
Neogen Corporation NEOG
$ 9.4
4.33%
Quarterly report 2026-Q1
added 04-09-2026
Neogen Corporation Cost of Revenue 2011-2026 | NEOG
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Neogen Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 473 M | 460 M | 416 M | 284 M | 253 M | 222 M | 222 M | 212 M | 190 M | 168 M | 143 M | 125 M | 98 M | 91.6 M | 84.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 473 M | 84.9 M | 230 M |
Quarterly Cost of Revenue Neogen Corporation
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 112 M | 118 M | 114 M | - | 111 M | 118 M | 112 M | - | 112 M | 113 M | 112 M | - | 110 M | 117 M | 70.1 M | 188 M | 70.8 M | 69.9 M | 68.3 M | 138 M | 62.9 M | 61.8 M | 59 M | 61.8 M | 54.5 M | 56.8 M | 53.2 M | 56.8 M | 53.2 M | 57.1 M | 52.9 M | 57.1 M | 50.4 M | 52.5 M | 49.4 M | 102 M | 47.5 M | 47.1 M | 43.2 M | 47.1 M | 43.2 M | 41.4 M | 37.1 M | 41.4 M | 34.7 M | 34.2 M | 33.5 M | 34.2 M | 33.5 M | 30.1 M | 28.2 M | 30.1 M | 28.2 M | 23.4 M | 23.2 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 188 M | 23.2 M | 66.9 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M | ||
|
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | ||
|
Agilent Technologies
A
|
2.91 B | $ 115.55 | 3.81 % | $ 35.1 B | ||
|
CareDx, Inc
CDNA
|
45.5 M | $ 20.81 | 0.05 % | $ 1.11 B | ||
|
Co-Diagnostics
CODX
|
222 K | $ 1.55 | 1.31 % | $ 2.06 M | ||
|
Castle Biosciences
CSTL
|
60.2 M | $ 24.49 | 1.03 % | $ 680 M | ||
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M | ||
|
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | ||
|
Fulgent Genetics
FLGT
|
176 M | $ 15.19 | 2.64 % | $ 459 M | ||
|
Aspira Women's Health
AWH
|
3.3 M | - | -6.19 % | $ 10.5 M | ||
|
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | ||
|
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
3.97 B | $ 118.33 | 1.86 % | $ 9.76 B | ||
|
Illumina
ILMN
|
1.51 B | $ 126.74 | 5.29 % | $ 20.2 B | ||
|
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | ||
|
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | ||
|
Lantheus Holdings
LNTH
|
600 M | $ 84.62 | 4.25 % | $ 5.71 B | ||
|
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | ||
|
Guardant Health
GH
|
349 M | $ 87.08 | 4.4 % | $ 10.9 B | ||
|
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K | ||
|
Koninklijke Philips N.V.
PHG
|
9.99 B | $ 26.34 | 2.95 % | $ 20 B | ||
|
Myriad Genetics
MYGN
|
248 M | $ 4.75 | 1.5 % | $ 440 M | ||
|
Interpace Biosciences
IDXG
|
14.6 M | $ 1.98 | -0.5 % | $ 8.76 M | ||
|
NeoGenomics
NEO
|
413 M | $ 9.26 | 3.35 % | $ 1.19 B | ||
|
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
4.81 M | $ 2.18 | 0.93 % | $ 5.01 M | ||
|
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 256.8 | -0.13 % | $ 21.4 B | ||
|
Natera
NTRA
|
158 M | $ 206.16 | 5.86 % | $ 20.3 B | ||
|
Invitae Corporation
NVTA
|
92.8 M | - | - | $ 21.2 M | ||
|
Quest Diagnostics Incorporated
DGX
|
7.37 B | $ 194.2 | 2.58 % | $ 21.6 B | ||
|
OpGen
OPGN
|
3.32 M | - | -16.95 % | $ 1.54 M | ||
|
Organovo Holdings
ONVO
|
5 K | - | -2.3 % | $ 19.4 M | ||
|
PerkinElmer
PKI
|
1.44 B | - | -0.91 % | $ 14.7 B | ||
|
Exagen
XGN
|
27.8 M | $ 2.9 | 5.07 % | $ 62.5 M | ||
|
Precipio
PRPO
|
13.3 M | $ 30.9 | 3.21 % | $ 49.6 M | ||
|
Burning Rock Biotech Limited
BNR
|
144 M | $ 17.0 | 4.68 % | $ 179 M | ||
|
Personalis
PSNL
|
57.8 M | $ 5.52 | 9.52 % | $ 327 M |